Prosecution Insights
Last updated: October 02, 2026
Application No. 18/025,847

CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE

Final Rejection §102
Filed
Mar 10, 2023
Priority
Sep 14, 2020 — provisional 63/077,969 +1 more
Examiner
VAJDA, KRISTIN ANN
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
GENZYME Corporation
OA Round
2 (Final)
84%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allowance Rate
1364 granted / 1624 resolved
+24.0% vs TC avg
Moderate +11% lift
Without
With
+10.9%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 9m
Avg Prosecution
42 currently pending
Career history
1653
Total Applications
across all art units

Statute-Specific Performance

§101
4.2%
-35.8% vs TC avg
§103
12.3%
-27.7% vs TC avg
§102
26.9%
-13.1% vs TC avg
§112
33.8%
-6.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1624 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-16 and 18-43 are pending in the instant application. Claims 6-8 and 24 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to non-elected subject matter. Claims 1, 2, 4, 5, 9-16, 18-22, 26-28, 34, 35, 37, and 43 are rejected. Claims 3, 23, 25, 29-33, 36, and 38-42 are objected. Response to Amendment and Arguments/Remarks The amendment and arguments/remarks filed on June 29, 2026 have been fully considered and entered into the application. With regards to the 35 U.S.C. 102(a)(1) rejection as being anticipated by U.S. Patent No. 5,977,108, the grounds for rejection are moot in view of Applicant’s amendment and the rejection has been withdrawn. However, this amendment has necessitated new grounds of rejection under 35 U.S.C. 102(a)(1), which are described below. Election/Restrictions It is noted that the search of the Markush-type claim has been extended to the non-elected species wherein: L is a bond; X is -CR7R8-; and the rest of the variables are as defined in the claims. As prior art has been found which anticipates the above identified nonelected species, the Markush-type claims are rejected as follows and the subject matter of the claims drawn to nonelected species held withdrawn from consideration. Claims 1-5, 9-16, 18-23, and 25-43 have been examined to the extent that they are readable on the elected embodiment and the above identified nonelected species. Since art was found on the nonelected species, subject matter not embraced by the elected embodiment or the above identified nonelected species is therefore withdrawn from further consideration. New Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 2, 4, 5, 9-16, 18-22, 26-28, 34, 35, 37, and 43 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by WO 2012/062777 A1. WO 2012/062777 A1 discloses the compound PNG media_image1.png 174 222 media_image1.png Greyscale (see claim 5) which anticipates a compound of Formula (I) of the claims wherein L is a bond; Ring C, Ring B and Ring A are thiazolylene; m, n and o are 0; X is -CR7R8- wherein R7 and R8 are H; Y is -N(H)-; and Z is Z1 wherein Z1 is H. Claim Objections Claims 3, 23, 25, 29-33, 36, and 40-42 are objected to for depending on a previous rejected claim. However, even if claims 40-42 are amended to be in independent form, they would still not be in condition for allowance because they contain non-elected subject matter. In other words, the subject matter or species which are not embraced by the elected embodiment or the above identified nonelected species have been withdrawn from further consideration. Claims 38 and 39 are objected to for containing non-elected subject matter (e.g., compound 2 wherein L is not a bond in claim 38). See above. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KRISTIN ANN VAJDA whose telephone number is (571)270-5232. The examiner can normally be reached Mon-Fri 6:00-4:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KRISTIN A VAJDA/Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Mar 10, 2023
Application Filed
Feb 04, 2026
Non-Final Rejection (signed) — §102
Apr 03, 2026
Non-Final Rejection mailed — §102
Jun 29, 2026
Response Filed
Sep 01, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12735391
POLYMORPHS OF PONESIMOD
2y 8m to grant Granted Sep 15, 2026
Patent 12734388
COMPOSITIONS AND USES OF TRANS-1,1,1,4,4,4-HEXAFLUORO-2-BUTENE AND 1,1-DIFLUOROETHANE (R-152A)
2y 4m to grant Granted Sep 15, 2026
Patent 12729191
PRODUCTION METHOD FOR SYNTHETIC INTERMEDIATE OF MONOCYCLIC PYRIDINE DERIVATIVE
2y 7m to grant Granted Sep 08, 2026
Patent 12729190
CORONAVIRUS MAIN PROTEASE INHIBITORS AND METHODS USING SAME
2y 7m to grant Granted Sep 08, 2026
Patent 12721834
COMBINATION TREATMENT FOR NETHERTON SYNDROME
2y 7m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
84%
Grant Probability
95%
With Interview (+10.9%)
1y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1624 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month